ArticleJournal of clinical and experimental hematopathology : JCEH2022
International definition of iMCD-TAFRO: future perspectives.
Article in Journal of clinical and experimental hematopathology : JCEH, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Case Report: Endothelial-targeted bridging therapy for a TTP-like phenotype in fulminant iMCD-TAFRO.Frontiers in immunology · 2026Article
- Successful Treatment of Refractory TAFRO Syndrome with Cyclophosphamide: A Report of Two Cases.Internal medicine (Tokyo, Japan) · 2025Article
- The Involvement of PI3K-Akt Signaling in the Clinical and Pathological Findings of Idiopathic Multicentric Castleman Disease-Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis, and Organomegaly and Not Otherwise Specified Subtypes.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2025Article
- Exploring the Clinical Diversity of Castleman Disease and TAFRO Syndrome: A Japanese Multicenter Study on Lymph Node Distribution Patterns.American journal of hematology · 2025Article
- Transcriptome analysis of the cytokine storm-related genes among the subtypes of idiopathic multicentric Castleman disease.Journal of clinical and experimental hematopathology : JCEH · 2024Article
- Increase in Vascular Endothelial Growth Factor (VEGF) Expression and the Pathogenesis of iMCD-TAFRO.Biomedicines · 2024Review
- TAFRO Syndrome and COVID-19.Biomedicines · 2024Review
- TAFRO Syndrome: Guidance for Managing Patients Presenting Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis, Renal Insufficiency, and Organomegaly.Biomedicines · 2024Review
- TAFRO Syndrome: A Syndrome or a Subtype of Multicentric Castleman Disease?Biomedicines · 2024Article
- Successful outcome in a case of idiopathic multicentric Castleman disease with atypical lymphadenopathy and kidney injury: Diagnostic challenges and treatment approach-Case report.SAGE open medical case reports · 2024Article
- Computed tomography findings of idiopathic multicentric Castleman disease subtypes.Journal of clinical and experimental hematopathology : JCEH · 2024Article
- Idiopathic Plasmacytic Lymphadenopathy Forms an Independent Subtype of Idiopathic Multicentric Castleman Disease.International journal of molecular sciences · 2022Article
- Castleman disease, TAFRO syndrome, idiopathic plasmacytic lymphadenopathy, and autoimmune disease.Journal of clinical and experimental hematopathology : JCEH · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly (TAFRO) syndrome was first proposed in 2010, there has been considerable progress in this area, particularly regarding its association with idiopathic multicentric Castleman disease (iMCD). TAFRO syndrome is a heterogeneous category with a constellation of symptoms that can develop in the setting of infection, rheumatologic disorder, malignancy, and iMCD. Now, iMCD with TAFRO symptoms is subtyped as iMCD-TAFRO. However, confusion between TAFRO syndrome and iMCD-TAFRO remains. In this article, we discuss the current understanding and future research agenda of TAFRO syndrome and iMCD-TAFRO from the perspective of its new validated international definition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.